Active, not recruitingPhase 2NCT04649359
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
Studying Multiple myeloma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pfizer
- Principal Investigator
- Pfizer CT.gov Call CenterPfizer
- Intervention
- Elranatamab (PF-06863135)(drug)
- Enrollment
- 187 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2026
Study locations (30)
- Beverly Hills Cancer Center, Beverly Hills, California, United States
- The Regents of the University of California, Irvine, California, United States
- Ronald Reagan UCLA Medical Center Drug information Center, Los Angeles, California, United States
- The Regents of the University of California, Los Angeles, California, United States
- UCLA Hematology/Oncology Clinic, Los Angeles, California, United States
- UCLA Ronald Reagan Medical Center, Los Angeles, California, United States
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange, California, United States
- Baptist Hospital of Miami, Miami, Florida, United States
- Winship Cancer Institute @ Emory University Hospital Midtown, Atlanta, Georgia, United States
- Emory University Hospital, Atlanta, Georgia, United States
- Emory University, Atlanta, Georgia, United States
- Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
- Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
- Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
- Northside Hospital, Atlanta, Georgia, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04649359 on ClinicalTrials.govOther trials for Multiple myeloma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07225738A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma PatientsCity of Hope Medical Center
- RECRUITINGPHASE3NCT06980480A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple MyelomaTakeda
- RECRUITINGPHASE4NCT07094048Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell EngagerCHU de Quebec-Universite Laval
- RECRUITINGPHASE3NCT07222761A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)Regeneron Pharmaceuticals
- RECRUITINGNANCT07226934An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic CancersWashington University School of Medicine
- RECRUITINGEARLY PHASE1NCT07294625A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple MyelomaThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1NCT07179679A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell TumorsChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- RECRUITINGPHASE3NCT06514508Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma PatientsGuangzhou Gloria Biosciences Co., Ltd.